Skip to main content
Erschienen in: Calcified Tissue International 5/2013

01.11.2013 | Original Research

Genetic Association Study of Dickkopf-1 and Sclerostin Genes with Paget Disease of Bone

verfasst von: Mariejka Beauregard, Edith Gagnon, Sabrina Guay-Bélanger, Ethel S. Siris, Jean Morissette, Jacques P. Brown, Laëtitia Michou

Erschienen in: Calcified Tissue International | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Increased expression of DKK1 gene was reported in pagetic osteoblasts and stromal cells, and increased serum levels of DKK1 and SOST proteins were reported in patients with Paget disease of bone (PDB). This study aimed at identifying rare genetic variants of the DKK1 and SOST genes and at testing for genetic association with PDB in the French-Canadian population. Exons, promoters, and exon–intron junctions of these genes were sequenced in patients with PDB and healthy controls. An association study of Tag SNPs of both genes was also performed in 239 pagetic patients and 297 healthy individuals. Three rare variants were identified in this study, all located in the DKK1 gene: one variant in the second exon leading to alteration in a highly conserved amino acid (p.R120L), one in the 5′-untranslated region (−50 C/A), and one in a splice site of intron 1 (IVS1 184 T/C), although none of these rare variants were associated with PDB. A genetic association of a Tag SNP of the DKK1 gene was found: the G allele of rs1569198 was significantly decreased in patients in comparison to controls (42 vs. 49 %, uncorrected P = 0.03, OR = 0.77, 95 % CI 0.61–0.98). In conclusion, this study identified three rare genetic variants in DKK1 in the French-Canadian population. In addition, a weak genetic association of a common variant of DKK1, rs1569198, which is located on a predicted new acceptor site for splicing of this gene, was observed in PDB, whereas no rare variant or genetic association was found in the SOST gene.
Literatur
1.
Zurück zum Zitat van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C (2002) Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res 17:465–471PubMedCrossRef van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C (2002) Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res 17:465–471PubMedCrossRef
2.
Zurück zum Zitat Goode A, Layfield R (2010) Recent advances in understanding the molecular basis of Paget’s disease of bone. J Clin Pathol 63:199–203PubMedCrossRef Goode A, Layfield R (2010) Recent advances in understanding the molecular basis of Paget’s disease of bone. J Clin Pathol 63:199–203PubMedCrossRef
3.
Zurück zum Zitat Roodman GD, Windle JJ (2005) Paget disease of bone. J Clin Invest 115:200–208PubMed Roodman GD, Windle JJ (2005) Paget disease of bone. J Clin Invest 115:200–208PubMed
4.
Zurück zum Zitat Laurin N, Brown JP, Morissette J, Raymond V (2002) Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 70:1582–1588PubMedCrossRef Laurin N, Brown JP, Morissette J, Raymond V (2002) Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 70:1582–1588PubMedCrossRef
5.
Zurück zum Zitat Morissette J, Laurin N, Brown JP (2006) Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget’s disease of bone. J Bone Miner Res 21(Suppl 2):P38–P44PubMedCrossRef Morissette J, Laurin N, Brown JP (2006) Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget’s disease of bone. J Bone Miner Res 21(Suppl 2):P38–P44PubMedCrossRef
6.
Zurück zum Zitat Chung PY, Van Hul W (2012) Paget’s disease of bone: evidence for complex pathogenetic interactions. Semin Arthritis Rheum 41:619–641PubMedCrossRef Chung PY, Van Hul W (2012) Paget’s disease of bone: evidence for complex pathogenetic interactions. Semin Arthritis Rheum 41:619–641PubMedCrossRef
7.
Zurück zum Zitat Hocking LJ, Lucas GJ, Daroszewska A, Cundy T, Nicholson GC, Donath J, Walsh JP, Finlayson C, Cavey JR, Ciani B, Sheppard PW, Searle MS, Layfield R, Ralston SH (2004) Novel UBA domain mutations of SQSTM1 in Paget’s disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res 19:1122–1127PubMedCrossRef Hocking LJ, Lucas GJ, Daroszewska A, Cundy T, Nicholson GC, Donath J, Walsh JP, Finlayson C, Cavey JR, Ciani B, Sheppard PW, Searle MS, Layfield R, Ralston SH (2004) Novel UBA domain mutations of SQSTM1 in Paget’s disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res 19:1122–1127PubMedCrossRef
8.
Zurück zum Zitat Betts AM, Clark TH, Yang J, Treadway JL, Li M, Giovanelli MA, Abdiche Y, Stone DM, Paralkar VM (2010) The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 333:2–13PubMedCrossRef Betts AM, Clark TH, Yang J, Treadway JL, Li M, Giovanelli MA, Abdiche Y, Stone DM, Paralkar VM (2010) The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 333:2–13PubMedCrossRef
9.
Zurück zum Zitat Albagha OM, Visconti MR, Alonso N, Langston AL, Cundy T, Dargie R, Dunlop MG, Fraser WD, Hooper MJ, Isaia G, Nicholson GC, del Pino MontesJ, Gonzalez-Sarmiento R, di Stefano M, Tenesa A, Walsh JP, Ralston SH (2010) Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget’s disease of bone. Nat Genet 42:520–524PubMedCrossRef Albagha OM, Visconti MR, Alonso N, Langston AL, Cundy T, Dargie R, Dunlop MG, Fraser WD, Hooper MJ, Isaia G, Nicholson GC, del Pino MontesJ, Gonzalez-Sarmiento R, di Stefano M, Tenesa A, Walsh JP, Ralston SH (2010) Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget’s disease of bone. Nat Genet 42:520–524PubMedCrossRef
10.
Zurück zum Zitat Albagha OM, Wani SE, Visconti MR, Alonso N, Goodman K, Brandi ML, Cundy T, Chung PY, Dargie R, Devogelaer JP, Falchetti A, Fraser WD, Gennari L, Gianfrancesco F, Hooper MJ, Van Hul W, Isaia G, Nicholson GC, Nuti R, Papapoulos S, del Montes P, Ratajczak T, Rea SL, Rendina D, Gonzalez-Sarmiento R, Di Stefano M, Ward LC, Walsh JP, Ralston SH (2011) Genome-wide association identifies three new susceptibility loci for Paget’s disease of bone. Nat Genet 43:685–689PubMedCrossRef Albagha OM, Wani SE, Visconti MR, Alonso N, Goodman K, Brandi ML, Cundy T, Chung PY, Dargie R, Devogelaer JP, Falchetti A, Fraser WD, Gennari L, Gianfrancesco F, Hooper MJ, Van Hul W, Isaia G, Nicholson GC, Nuti R, Papapoulos S, del Montes P, Ratajczak T, Rea SL, Rendina D, Gonzalez-Sarmiento R, Di Stefano M, Ward LC, Walsh JP, Ralston SH (2011) Genome-wide association identifies three new susceptibility loci for Paget’s disease of bone. Nat Genet 43:685–689PubMedCrossRef
11.
Zurück zum Zitat Marshall MJ, Evans SF, Sharp CA, Powell DE, McCarthy HS, Davie MW (2009) Increased circulating Dickkopf-1 in Paget’s disease of bone. Clin Biochem 42:965–969PubMedCrossRef Marshall MJ, Evans SF, Sharp CA, Powell DE, McCarthy HS, Davie MW (2009) Increased circulating Dickkopf-1 in Paget’s disease of bone. Clin Biochem 42:965–969PubMedCrossRef
13.
Zurück zum Zitat Yavropoulou MP, van Lierop AH, Hamdy NA, Rizzoli R, Papapoulos SE (2012) Serum sclerostin levels in Paget’s disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone 51:153–157PubMedCrossRef Yavropoulou MP, van Lierop AH, Hamdy NA, Rizzoli R, Papapoulos SE (2012) Serum sclerostin levels in Paget’s disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone 51:153–157PubMedCrossRef
14.
Zurück zum Zitat Naot D, Bava U, Matthews B, Callon KE, Gamble GD, Black M, Song S, Pitto RP, Cundy T, Cornish J, Reid IR (2007) Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget’s disease of bone. J Bone Miner Res 22:298–309PubMedCrossRef Naot D, Bava U, Matthews B, Callon KE, Gamble GD, Black M, Song S, Pitto RP, Cundy T, Cornish J, Reid IR (2007) Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget’s disease of bone. J Bone Miner Res 22:298–309PubMedCrossRef
15.
Zurück zum Zitat Costa AG, Bilezikian JP (2012) Sclerostin: therapeutic horizons based upon its actions. Curr Osteoporos Rep 10:64–72PubMedCrossRef Costa AG, Bilezikian JP (2012) Sclerostin: therapeutic horizons based upon its actions. Curr Osteoporos Rep 10:64–72PubMedCrossRef
16.
Zurück zum Zitat Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL (2010) Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87:99–107PubMedCrossRef Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL (2010) Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87:99–107PubMedCrossRef
17.
Zurück zum Zitat Uitterlinden AG, Arp PP, Paeper BW, Charmley P, Proll S, Rivadeneira F, Fang Y, van Meurs JB, Britschgi TB, Latham JA, Schatzman RC, Pols HA, Brunkow ME (2004) Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites. Am J Hum Genet 75:1032–1045PubMedCrossRef Uitterlinden AG, Arp PP, Paeper BW, Charmley P, Proll S, Rivadeneira F, Fang Y, van Meurs JB, Britschgi TB, Latham JA, Schatzman RC, Pols HA, Brunkow ME (2004) Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites. Am J Hum Genet 75:1032–1045PubMedCrossRef
18.
Zurück zum Zitat Frazer KA, Murray SS, Schork NJ, Topol EJ (2009) Human genetic variation and its contribution to complex traits. Nat Rev Genet 10:241–251PubMedCrossRef Frazer KA, Murray SS, Schork NJ, Topol EJ (2009) Human genetic variation and its contribution to complex traits. Nat Rev Genet 10:241–251PubMedCrossRef
19.
Zurück zum Zitat Laberge AM (2007) Prevalence and distribution of genetic diseases in Quebec: impact of the past on the present [in French]. Med Sci (Paris) 23:997–1001CrossRef Laberge AM (2007) Prevalence and distribution of genetic diseases in Quebec: impact of the past on the present [in French]. Med Sci (Paris) 23:997–1001CrossRef
20.
Zurück zum Zitat Bodmer W, Bonilla C (2008) Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 40:695–701PubMedCrossRef Bodmer W, Bonilla C (2008) Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 40:695–701PubMedCrossRef
21.
Zurück zum Zitat Moreau C, Vezina H, Labuda D (2007) Founder effects and genetic variability in Quebec [in French]. Med Sci (Paris) 23:1008–1013CrossRef Moreau C, Vezina H, Labuda D (2007) Founder effects and genetic variability in Quebec [in French]. Med Sci (Paris) 23:1008–1013CrossRef
22.
Zurück zum Zitat Laurin N, Brown JP, Lemainque A, Duchesne A, Huot D, Lacourciere Y, Drapeau G, Verreault J, Raymond V, Morissette J (2001) Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet 69:528–543PubMedCrossRef Laurin N, Brown JP, Lemainque A, Duchesne A, Huot D, Lacourciere Y, Drapeau G, Verreault J, Raymond V, Morissette J (2001) Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet 69:528–543PubMedCrossRef
24.
Zurück zum Zitat Michou L, Morissette J, Gagnon ER, Marquis A, Dellabadia M, Brown JP, Siris ES (2011) Novel SQSTM1 mutations in patients with Paget’s disease of bone in an unrelated multiethnic American population. Bone 48:456–460PubMedCrossRef Michou L, Morissette J, Gagnon ER, Marquis A, Dellabadia M, Brown JP, Siris ES (2011) Novel SQSTM1 mutations in patients with Paget’s disease of bone in an unrelated multiethnic American population. Bone 48:456–460PubMedCrossRef
25.
Zurück zum Zitat Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30:3894–3900PubMedCrossRef Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30:3894–3900PubMedCrossRef
26.
Zurück zum Zitat Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073–1081PubMedCrossRef Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073–1081PubMedCrossRef
27.
Zurück zum Zitat Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C (2009) Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37:e67PubMedCrossRef Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C (2009) Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37:e67PubMedCrossRef
28.
Zurück zum Zitat Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555–1565PubMedCrossRef Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555–1565PubMedCrossRef
29.
Zurück zum Zitat Korvala J, Loija M, Makitie O, Sochett E, Juppner H, Schnabel D, Mora S, Cole WG, Ala-Kokko L, Mannikko M (2012) Rare variations in WNT3A and DKK1 may predispose carriers to primary osteoporosis. Eur J Med Genet 55:515–519PubMedCrossRef Korvala J, Loija M, Makitie O, Sochett E, Juppner H, Schnabel D, Mora S, Cole WG, Ala-Kokko L, Mannikko M (2012) Rare variations in WNT3A and DKK1 may predispose carriers to primary osteoporosis. Eur J Med Genet 55:515–519PubMedCrossRef
30.
Zurück zum Zitat Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33:747–783PubMedCrossRef Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33:747–783PubMedCrossRef
31.
Zurück zum Zitat Baron R, Hesse E (2012) Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab 97:311–325PubMedCrossRef Baron R, Hesse E (2012) Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab 97:311–325PubMedCrossRef
32.
Zurück zum Zitat Hoeppner LH, Secreto FJ, Westendorf JJ (2009) Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 13:485–496PubMedCrossRef Hoeppner LH, Secreto FJ, Westendorf JJ (2009) Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 13:485–496PubMedCrossRef
33.
Zurück zum Zitat McCarthy HS, Marshall MJ (2010) Dickkopf-1 as a potential therapeutic target in Paget’s disease of bone. Expert Opin Ther Targets 14:221–230PubMedCrossRef McCarthy HS, Marshall MJ (2010) Dickkopf-1 as a potential therapeutic target in Paget’s disease of bone. Expert Opin Ther Targets 14:221–230PubMedCrossRef
34.
Zurück zum Zitat Daoussis D, Andonopoulos AP (2011) The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling? Semin Arthritis Rheum 41:170–177PubMedCrossRef Daoussis D, Andonopoulos AP (2011) The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling? Semin Arthritis Rheum 41:170–177PubMedCrossRef
35.
Zurück zum Zitat Menezes ME, Devine DJ, Shevde LA, Samant RS (2012) Dickkopf1: a tumor suppressor or metastasis promoter? Int J Cancer 130:1477–1483PubMedCrossRef Menezes ME, Devine DJ, Shevde LA, Samant RS (2012) Dickkopf1: a tumor suppressor or metastasis promoter? Int J Cancer 130:1477–1483PubMedCrossRef
Metadaten
Titel
Genetic Association Study of Dickkopf-1 and Sclerostin Genes with Paget Disease of Bone
verfasst von
Mariejka Beauregard
Edith Gagnon
Sabrina Guay-Bélanger
Ethel S. Siris
Jean Morissette
Jacques P. Brown
Laëtitia Michou
Publikationsdatum
01.11.2013
Verlag
Springer US
Erschienen in
Calcified Tissue International / Ausgabe 5/2013
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-013-9762-2

Weitere Artikel der Ausgabe 5/2013

Calcified Tissue International 5/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.